Stock Events

Stock Events

Yarrow Bioscience 

$42.07
54
+$0.55+1.32% 14:29 Today

Statistics

Day High
42.5
Day Low
41.26
52W High
46.95
52W Low
14.05
Volume
11,468
Avg. Volume
20,057
Mkt Cap
112.32M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Jul 26
$0.40
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

5NovExpected
Q1 2026
Q2 2026
Next
-32.5
-22.38
-12.26
-2.14
Expected EPS
-16
Actual EPS
N/A

Financials

-4,646.14%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
570,000Revenue
-26.48MNet Income

Analyst Ratings

58.00Average Price Target
The highest estimate is 58.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow YARW. It's not an investment recommendation.
Apple
6
AAPL
Bionano Genomics
6
BNGO
NIO
5
NIO
Fuelcell Energy
5
FCEL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotech company that develops treatments in areas similar to VYNE, including dermatology and inflammatory diseases.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie competes in the dermatology space with its portfolio of drugs, directly challenging VYNE's therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap627.42B
Johnson & Johnson, through its pharmaceutical division Janssen, offers products that compete in the dermatological and autoimmune sectors against VYNE.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad range of products that include treatments for conditions VYNE targets, making them a direct competitor.
Merck
MRK
Mkt Cap335.14B
Merck operates in similar therapeutic areas as VYNE, including anti-inflammatory and dermatological conditions.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences focuses on inflammatory and respiratory diseases, competing with VYNE's product offerings.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals specializes in biopharmaceuticals for dermatology, directly competing with VYNE.
Novartis
NVS
Mkt Cap286.78B
Novartis offers products in dermatology and chronic diseases, areas where VYNE is also active.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb has a diverse portfolio that includes treatments for immune-mediated diseases, competing with VYNE.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca has a focus on respiratory, cardiovascular, and autoimmune diseases, overlapping with VYNE's focus areas.

About

Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
Show more...
CEO
Rebecca Velez Frey
Employees
10
Country
United States
ISIN
US92941V4077

Listings

XNAS
US
VYNE
XNAS
US
YARW
BOATS
BOATS
VYNE.BOATS

0 Comments

Share your thoughts

FAQ

What is Yarrow Bioscience stock price today?▼
The current price of YARW is $42.07 USD — it has increased by +1.32% in the past 24 hours. Watch Yarrow Bioscience stock price performance more closely on the chart.
What is Yarrow Bioscience stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Yarrow Bioscience stocks are traded under the ticker YARW.
What is Yarrow Bioscience market cap?▼
Today Yarrow Bioscience has the market capitalization of 112.32M
When is the next Yarrow Bioscience earnings date?▼
Yarrow Bioscience is going to release the next earnings report on November 05, 2026.
What were Yarrow Bioscience earnings last quarter?▼
YARW earnings for the last quarter are -2.14 USD per share, whereas the estimation was -11 USD resulting in a +80.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Yarrow Bioscience revenue for the last year?▼
Yarrow Bioscience revenue for the last year amounts to 570,000 USD.
What is Yarrow Bioscience net income for the last year?▼
YARW net income for the last year is -26.48M USD.
Does Yarrow Bioscience pay dividends?▼
Yes, YARW dividends are paid en. The last dividend per share was 0.4 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Yarrow Bioscience have?▼
As of August 19, 2026, the company has 10 employees.
In which sector is Yarrow Bioscience located?▼
Yarrow Bioscience operates in the Health & Wellness sector.
When did Yarrow Bioscience complete a stock split?▼
Yarrow Bioscience has not had any recent stock splits.
Where is Yarrow Bioscience headquartered?▼
Yarrow Bioscience is headquartered in NEW HAVEN, United States.